Orilotimod potassium

Drug Profile

Orilotimod potassium

Alternative Names: Apo-805; Apo-805K1

Latest Information Update: 09 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ApoPharma
  • Class Antipsoriatics; Essential amino acids; Potassium compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Plaque psoriasis

Most Recent Events

  • 01 Oct 2013 ApoPharma completes a phase II trial in Plaque psoriasis in USA (NCT01483924)
  • 30 Nov 2011 Phase-II clinical trials in Plaque psoriasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top